Commercial human albumin preparations for clinical use are immunosuppressive in vitro

Critical Care Medicine

Volumn 34, Issue 6, 2006, Pages 1707-1712

  Bar Or, David ^a,b   Thomas, Gregory W ^b   Bar Or, Raphael ^b   Rael, Leonard T ^b   Scarborough, Kristin ^b   Rao, Nagaraja ^c   Shimonkevitz, Richard ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b DMI BioSciences Inc   (United States)

^c DMI BioSciences Synthesis   (United Kingdom)

Author keywords

Cytokine; Diketopiperazine; Human serum albumin; Peripheral blood mononuclear cells; T lymphocyte

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; PIPERAZINEDIONE; SERUM ALBUMIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AMINO TERMINAL SEQUENCE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE CLONE; LYMPHOCYTE CULTURE; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN ISOLATION; T LYMPHOCYTE ACTIVATION;

CELL LINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; LEUKOCYTES, MONONUCLEAR; MALE; MASS SPECTROMETRY; SERUM ALBUMIN; T-LYMPHOCYTES;

EID: 33744528587     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000217923.53680.4C     Document Type: Article

References (19)

1. Martin GS, Moss M, Wheler AP, et al: A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 2005; 33:1681-1687
2. Quinlan GJ, Mumby S, Martin GS, et al: Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004; 32:755-759
3. The SAFE Study Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256
4. American Thoracic Society Critical Care Assembly subcommittee: Evidence-based colloid use in the critically ill: American Thoracic Society consensus statement. Am J Respir Crit Care Med 2004; 170:1247-1259
5. Wilkes MM, Navickis RJ: Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 135:149-164
6. von Hoegen I, Waller C: Safety of human albumin based on spontaneously reported serious adverse events. Crit Care Med 2001; 29:994-996
7. Sort P, Navasa M, Arroyo V, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409
8. Cochrane Injuries Group Albumin Reviewers: Human albumin administration in critically ill patients: Systematic review of randomized controlled trials. BMJ 1998; 317:235-240
9. Bar-Or D, Bar-Or R, Rael LT, et al: Heterogeneity and oxidation status of commercial albumin preparations in clinical use. Crit Care Med 2005; 33:1638-1641
10. Battersby JE, Hancock WS, Canova-Davis E, et al: Diketopiperazine formation and N-terminal degradation in recombinant human growth hormone. Int J Pept Protein Res 1994; 44:215-222
11. Prasad C: Cyclo(His-Pro): Its distribution, origin and function in the human. Neurosci Biobehav Rev 1988; 12:19-22
12. Takahara Y, Battaini F, Ross DD, et al: Detection in human serum by radioimmunoassay of histidyl-proline diketopiperazine, a metabolite of thyrotropin-releasing hormone. J Clin Endocrinol Metab 1983; 56:312-319
13. Chan B, Dodsworth N, Woodrow J, et al: Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995; 227:524-528
14. Goolcharran C, Borchardt RT: Kinetics of diketopiperazine formation using model peptides. J Pharm Sci 1998; 87:283-288
15. Goolcharran C, Cleland JL, Keck R, et al: Comparison of the rates of deamidation, diketopiperazine formation and oxidation of recombinant human vascular endothelial growth factor and model peptides. AAPS PharmSci 2000; 2:E5
16. Lin SY, Wang SL, Chen TF, et al: Intramolecular cyclization of diketopiperazine formation in solid-state enalapril maleate studied by thermal FT-IR microscopic system. Eur J Pharm Biopharm 2002; 54:249-254
17. Purdie J, Benoiton NL: Piperazine formation from esters of dipeptides containing glycine, alanine, and sarcosine: the kinetics in aqueous solution. J Chem Soc 1973; 13:1845-1852
18. ABPI Compedium of Data Sheets and Summaries of Products Characteristics 1998-99. London: Association of the British Pharmaceutical Industries, 1998
19. Martin GS: Pharmacological aspects of albumin as a niche product in the intensive care unit. Crit Care Med 2005; 33:1667-1669